Please login to the form below

Not currently logged in
Email:
Password:

GSK partners with new science hub the Francis Crick Institute

Will work with the biomedical facility on an 'open innovation' basis

GSK HQ 

GlaxoSmithKline has signed a deal with the UK's newest biomedical research facility The Francis Crick Institute to help the firm with its drug development. 

The two groups will work on an 'open innovation' collaboration exploring new avenues of medical research and drug discovery across a broad range of diseases.

This is the first collaboration to be established between the Crick Institute - which incorporates both the Medical Research Council's National Institute for Medical Research and Cancer Research UK's London Research Institute - and a pharmaceutical company.

Teams of scientists from each organisation will work side-by-side in integrated teams at the Crick's world-leading centre of biomedical research in central London and GSK's global R&D hub in Stevenage. 

In a statement, GSK said: “The close proximity of these two sites and the institutions' complementary areas of expertise will create a fertile ground for collaborative, innovative research - exposing scientists to new ways of thinking and building capability within each organisation.”

Both Crick and GSK said that their scientists will see a major benefit from the collaboration by introducing new ways of working and stimulating the development of novel approaches to problems. 

The two groups will contribute in-kind resources, including lab space and the scientific expertise of 20 staff to the collaboration. 

GSK will also provide important research tools to the collaboration, including access to its non-development compound library, key antibodies, reagents and technologies.

A number of projects within this collaboration exploring diseases including HIV, malaria and cancer are expected to start in 2015, according to the firm, which will build up to 10-15 projects by next year.

GSK's president of pharmaceuticals R&D, Patrick Vallance, said: “As a company with deep research roots in the UK, we're enormously proud of this country's vibrant biosciences community and the cutting-edge biomedical research that takes place here. 

“That's why we continue to invest a quarter of our R&D spend in the UK and have collaborations in place with some of the country's top research institutions, which rank among the best in the world.”

Article by
Ben Adams

15th July 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics